Atsena Therapeutics and Nippon Shinyaku Enter Exclusive License Agreement for ATSN-101

Atsena Therapeutics and Nippon Shinyaku have formed an exclusive licensing agreement for ATSN-101, a gene therapy for Leber congenital amaurosis (LCA1). Nippon Shinyaku will commercialize ATSN-101 in the U.S. and Japan, while Atsena retains global rights outside these territories.

Atsena Therapeutics Inc., a UF Startup, has entered into an exclusive license agreement with Nippon Shinyaku Co., Ltd. for the commercialization of ATSN-101 in the United States, and for its development and commercialization in Japan. This collaboration aims to advance ATSN-101, an investigational gene therapy for Leber congenital amaurosis (LCA) caused by biallelic mutations in the GUCY2D gene (LCA1).

Under the terms of the agreement, Nippon Shinyaku will hold exclusive commercial rights for ATSN-101 in both the US and Japan. Atsena will retain commercial rights in all other regions worldwide. In the U.S., ATSN-101 will be marketed by NS Pharma Inc., a wholly-owned subsidiary of Nippon Shinyaku.

Read more about Atsena Therapeutics and Nippon Shinyaku Enter Exclusive License Agreement for ATSN-101.